Free Trial
→ The chokepoint supplier behind SpaceX's $1.75 trillion empire (From Behind the Markets) (Ad)tc pixel
NYSEAMERICAN:MAIA

MAIA Biotechnology Q4 2025 Earnings Report

MAIA Biotechnology logo
$1.39 0.00 (0.00%)
Closing price 04:10 PM Eastern
Extended Trading
$1.38 -0.01 (-0.72%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings History

MAIA Biotechnology EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.13
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

MAIA Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MAIA Biotechnology Announcement Details

Quarter
Q4 2025
Date
3/23/2026
Time
Before Market Opens
Conference Call Date
Monday, March 23, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

MAIA Biotechnology's Q1 2026 earnings is estimated for Friday, May 8, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

MAIA Biotechnology's Q4 2025 Annual reportAnnual report
(10-K)

MAIA Biotechnology Earnings Headlines

MAIA Biotechnology (MAIA) to Release Earnings on Friday
May 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30750731
MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer
April 16, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/maia-biotechnology-activates-first-u-s-site-for-ongoing-international-phase-2-expansion-trial-of-novel-telomere-targeting-treatment-targeting-advanced-non-small-cell-lung-cancer-1036029197
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
May 5 at 1:00 AM  |  Brownstone Research (Ad)
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
April 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/08/3270148/0/en/maia-biotechnology-expects-recent-33-million-capital-raise-to-fully-fund-ongoing-pivotal-phase-3-trial-of-novel-telomere-targeting-anticancer-therapy.html
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3265650/0/en/maia-biotechnology-reports-overall-survival-exceeding-two-years-for-eight-patients-in-ongoing-phase-2-clinical-trial-in-non-small-cell-lung-cancer.html
MAIA Biotechnology (MAIA) price target increased by 18.16% to 12.38
March 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/maia-biotechnology-maia-price-target-increased-by-1816-to-1238/ar-AA1ZwYgd
See More MAIA Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MAIA Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MAIA Biotechnology and other key companies, straight to your email.

About MAIA Biotechnology

MAIA Biotechnology (NYSEAMERICAN:MAIA) is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods. In parallel, MAIA Biotechnology is advancing therapeutic constructs that couple monoclonal antibodies to therapeutic radioisotopes for selective tumor cell eradication. These efforts are supported by in‐house radiochemistry capabilities and collaborative research partnerships with academic institutions.

Headquartered in the United States, MAIA Biotechnology serves both domestic and international research markets and is preparing key assets for regulatory submission and first‐in‐human trials. The management team comprises industry veterans in radiopharmaceutical development and antibody engineering, and the company continues to expand its platform technology to address unmet needs in cancer diagnosis and treatment.

View MAIA Biotechnology Profile
Earnings Tools